Drug Trial Radar · NCT06277128
A Study to Evaluate the Safety and Efficacy of WS016 in Patients With Hyperkalemia.
Last checked: Nov 19, 2026Latest source record: Feb 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
140
Planned (sponsor's estimate)
Start
Sep 11, 2023
Primary completion
Apr 18, 2024
Study completion Aug 4, 2024
Sponsor
- Lead sponsor
- Waterstone Pharmaceutical (Wuhan) Co., LTD.Industry
- Sponsor type
- Industry
- First posted
- Feb 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the efficacy of different doses of WS016(3g, 6g and 12g) orally administered three times a day for 48 hours (acute treatment phase) vs placebo in the treatment of hyperkalemia, and to evaluate the efficacy of WS016(3g, 6g and 12g) orally administered once daily for 12 days ( maintenance treatment phase) vs placebo in maintaining normokalemia in participants have returned to normokalemia after the acute treatment phase.
Conditions
- Hyperkalemia
Interventions
WS016 3gDrug
Acute treatment phase: WS016, oral, 3g , three times a day for 48 hours; Maintenance treatment phase: WS016, oral, 3g, once daily for 12 days.
WS016 6gDrug
Acute treatment phase: WS016, oral, 6g , three times a day for 48 hours; Maintenance treatment phase: WS016, oral, 6g, once daily for 12 days.
WS016 12gDrug
Acute treatment phase: WS016, oral, 12g , three times a day for 48 hours; Maintenance treatment phase: WS016, oral, 12g, once daily for 12 days.
Matching PlaceboDrug
Acute treatment phase: Matching Placebo, oral, three times a day for 48 hours; Maintenance treatment phase: Matching Placebo, oral, once daily for 12 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Exponential rate of change in serum potassium(S-K) levels during the acute treatment phaseTime frame: Through the initial 48-hour acute treatment phase (from baseline to hour 48)
- Exponential rate of change in S-K levels during the maintenance treatment phaseTime frame: Through 12 days of maintenance treatment phase (from Day 3 to Day 15)
Locations
26 sites in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, Beijing Municipality, China · Recruiting
Peking University Shougang Hospital
Beijing, Beijing Municipality, China · Recruiting
Zhongshan Hospital, Xiamen University
Xiamen, Fujian, China · Recruiting
The Affiliated Hospital of Hebei University
Baoding, Hebei, China · Recruiting
Hebei Traditional Chinese Medicine Hospital
Shijiazhuang, Hebei, China · Recruiting
The Second Hospital of Hebei Medical University
Shijiazhuang, Hebei, China · Recruiting
The First Hospital of Qiqihar
Qiqihar, Heilongjiang, China · Recruiting
The First People's Hospital of Nanyang City
Nanyang, Henan, China · Recruiting
Puyang Oilfield General Hospital
Puyang, Henan, China · Recruiting
Shiyan Taihe Hospital
Shiyan, Hubei, China · Recruiting
Wuhan No.4 Hospital
Wuhan, Hubei, China · Recruiting
Zhuzhou Central Hospital
Zhuzhou, Hunan, China · Recruiting
Affiliated Hospital of Inner Mongolia Medical University
Hohhot, Inner Mongolia, China · Recruiting
Sir Run Run Hospital, Nanjing Medical University
Nanjing, Jiangsu, China · Recruiting
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China · Recruiting
The Affiliated Hospital of Nantong University
Nantong, Jiangsu, China · Recruiting
Shenyang Central Hospital, affiliated to Shenyang Medical College
Shenyang, Liaoning, China · Recruiting
General Hospital of Ningxia Medical University
Yinchuan, Ningxia, China · Recruiting
The First People's Hospital of Tancheng County
Linyi, Shandong, China · Recruiting
Qilu Hospital of Shandong University (Qingdao)
Qingdao, Shandong, China · Recruiting
Minhang District Central Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Shanghai First People's Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Shanghai No.5 Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Shanghai Tongji Hospital
Shanghai, Shanghai Municipality, China · Recruiting
The Second Affiliated Hospital of Tianjin Medical University
Tianjin, Tianjin Municipality, China · Recruiting
Tianjin People's Hospital
Tianjin, Tianjin Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.